MaxCyte, Inc. provided revenue guidance for the full year 2022. For the period, the company expected core business revenue (instruments and disposables to cell therapy and drug discovery customers and excluding program-related revenue) to grow at least 25% compared to 2021 core business revenue. The company also continue to expect SPL Program-related revenue to be approximately $4 million in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
375 GBX | +1.35% | +5.04% | +6.38% |
05-22 | MaxCyte inks deal with Legend Biotech for tech supply | AN |
05-22 | MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.38% | 492M | |
+8.96% | 222B | |
+13.70% | 195B | |
+23.11% | 148B | |
+32.88% | 113B | |
+4.18% | 66.45B | |
+12.90% | 53.11B | |
+3.16% | 50.03B | |
-4.76% | 38.8B | |
-2.30% | 34.85B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022